Atyr Pharma Inc. (NASDAQ:LIFE)’s share price was down 2.7% during trading on Monday . The company traded as low as $3.23 and last traded at $3.25, with a volume of 155,923 shares traded. The stock had previously closed at $3.34.

A number of equities analysts have commented on LIFE shares. Zacks Investment Research raised shares of Atyr Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. BMO Capital Markets reaffirmed a “hold” rating on shares of Atyr Pharma in a research report on Thursday, May 12th. JPMorgan Chase & Co. reduced their price objective on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Finally, Citigroup Inc. lifted their price objective on shares of Atyr Pharma from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 16th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $6.00.

The firm’s market capitalization is $77.08 million. The stock’s 50 day moving average price is $3.05 and its 200 day moving average price is $3.66.

Atyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. Equities analysts forecast that Atyr Pharma Inc. will post ($2.63) EPS for the current year.

An institutional investor recently raised its position in Atyr Pharma stock. RS Investment Management Co. LLC increased its position in shares of Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned approximately 5.10% of Atyr Pharma worth $11,857,000 at the end of the most recent quarter.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.